{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:53:50Z","timestamp":1782921230201,"version":"3.54.5"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi260584-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Enfortumab vedotin plus pembrolizumab (EV\/P) recently emerged as the preferred first-line treatment regimen for metastatic urothelial carcinoma (mUC), but evidence outside trial settings is relatively limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260584-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate outcomes associated with first-line EV\/P compared with gemcitabine plus cisplatin (G\/C) in patients with mUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260584-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study used the TriNetX database. Adults with mUC initiating first-line EV\/P or G\/C between September 2007 and September 2025 were included. Cohorts were propensity score matched for comparison by demographic characteristics, comorbidities, kidney function, and location of metastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260584-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was overall survival (OS). Secondary outcomes included time to next treatment (TTNT), time to hospitalization within 90 days of treatment initiation (EHA), and adverse events (AEs). Outcomes were compared using Kaplan-Meier analysis and log rank test, reporting hazard ratios (HRs) and 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260584-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 4433 patients (1841 receiving EV\/P and 2592 receiving G\/C), with the EV\/P group being significantly older (mean [SD] age, 70.6 [10.1] years vs 67.2 [10.6] years;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and having a higher proportion of Black patients (129 [6.7%] vs 139 [5.3%];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04) and White patients (1445 [76.0%] vs 1614 [61.8%]) but a smaller proportion of Asian patients (145 [7.6%] vs 326 [12.5%];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The EV\/P group also carried a greater comorbidity burden, including higher rates of heart failure, diabetes, and obesity, while baseline characteristics were well balanced after propensity score matching. First line EV\/P was associated with lower risk of death (HR, 0.70; 95% CI, 0.63-0.79), longer median OS (20 vs 11 months), lower risk of EHA (HR, 0.73; 95% CI, 0.64-0.83), and longer TTNT (median, 35 vs 10 months; HR, 0.49; 95% CI, 0.39-0.61). Receipt of EV\/P at first line was associated with higher rates of rash, hyperglycemia, and hypothyroidism but fewer cytopenias and gastrointestinal toxic effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260584-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this retrospective cohort study of patients with mUC, EV\/P was associated with longer OS, delayed TTNT, and lower time to EHA compared with G\/C. These findings support the broader adoption of EV\/P as first-line therapy in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.21032","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:39:11Z","timestamp":1782920351000},"page":"e2621032","source":"Crossref","is-referenced-by-count":0,"title":["First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Eusebio Luna","family":"Velasquez","sequence":"first","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renil S.","family":"Titus","sequence":"additional","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David-Dan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Riveros","sequence":"additional","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly-Khan","family":"Lalani","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharam","family":"Kaushik","sequence":"additional","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Advent Health Cancer Institute and University of Central Florida, Orlando"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine; Fred Hutchinson Cancer Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[{"name":"Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[{"name":"Department of Urology, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"11","key":"zoi260584r1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10236","key":"zoi260584r2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"zoi260584r3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer.","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260584r4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma.","volume":"18","author":"Heath","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"11","key":"zoi260584r5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi260584r6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi260584r7","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer.","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi260584r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial.","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"21","key":"zoi260584r9","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi260584r10","doi-asserted-by":"publisher","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol Oncol"},{"issue":"57","key":"zoi260584r11","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data.","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"zoi260584r12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e16548","article-title":"Treating the untended: Real-world insights into enfortumab vedotin plus pembrolizumab for frail metastatic urothelial carcinoma patients excluded or underrepresented in clinical trials (GUARDIANS).","volume":"43","author":"Aydogdu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260584r13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.2025.43.5_suppl.715","article-title":"Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).","volume":"43","author":"Zschaebitz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi260584r14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer.","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"key":"zoi260584r16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"issue":"23","key":"zoi260584r17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2217\/fon-2022-0616","article-title":"Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors.","volume":"19","author":"Agapow","year":"2023","journal-title":"Future Oncol"},{"issue":"10","key":"zoi260584r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12823","article-title":"Development and validation of a score to predict acute care use after initiation of systemic therapy for cancer.","volume":"2","author":"Grant","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260584r19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ptj\/pzz192","article-title":"The correlative strength of objective physical assessment against the ECOG performance status assessment in individuals diagnosed with cancer.","volume":"100","author":"Quinn","year":"2020","journal-title":"Phys Ther"},{"issue":"8","key":"zoi260584r20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10147-020-01690-1","article-title":"Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis.","volume":"25","author":"Mori","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"zoi260584r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0250","article-title":"Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: a systematic review and meta-analysis.","volume":"8","author":"Yajima","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260584r22","doi-asserted-by":"publisher","first-page":"S1149","DOI":"10.1016\/j.annonc.2024.08.2073","article-title":"1988P enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients with advanced urothelial carcinoma: analysis of the UNITE study.","volume":"35","author":"Jindal","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi260584r23","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/j.clgc.2022.06.001","article-title":"Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma.","volume":"20","author":"Makrakis","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"zoi260584r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.","volume":"10","author":"van der Heijden","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"zoi260584r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102453","article-title":"Real-world outcomes of enfortumab vedotin and pembrolizumab in advanced urothelial carcinoma: a multicenter retrospective analysis.","volume":"23","author":"Jain","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"zoi260584r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100110","article-title":"Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network.","volume":"7","author":"Li","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"5","key":"zoi260584r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9417","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US.","volume":"7","author":"Mathew Thomas","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260584r28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00262-024-03910-3","volume":"74","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"zoi260584r15","unstructured":"TriNetX. TriNetX: Real-world data and analytics platform. Accessed May 26, 2026. https:\/\/trinetx.com"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851023\/velasquez_2026_oi_260584_1782838598.44817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:39:15Z","timestamp":1782920355000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.21032","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}